ABCD2: A Promising Drug Target and Biomarker for ALD1-Induced Neutrophil Inflammation

Target Name: ABCD2

NCBI ID: G225

ABCD2

ABCD2: A Promising Drug Target and Biomarker for ALD1-Induced Neutrophil Inflammation

Acute respiratory distress syndrome (ARDS) is a life-threatening condition that arises from an inflammatory response to an underlying cause, often caused by an infection or injury. The leading cause of ARDS is an excessive accumulation of neutrophils, which are a type of white blood cell that play a crucial role in fighting bacterial infections but can also cause tissue damage in excessive numbers. One of the main risk factors for ARDS is an underlying underlying lung disease or injury, such as chronic obstructive pulmonary disease (COPD) or traumatic injury, which can lead to chronic inflammation and an increase in the population with pre-existing conditions that make them more susceptible to ARDS.

The drug target ABCD2 has shown great potential as a treatment for ARDS due to its unique mechanism of action and its ability to modulate the inflammatory response. In this article, we will discuss the biology of ABCD2, its potential as a drug target and biomarker for ARDS, and the ongoing clinical trials evaluating its effectiveness.

Biomarker and Drug Target

ABCD2 is a gene that encodes a protein known as AIMP-2, which stands for Activated Integrins on Memory Peptides. Activated integrins are a family of proteins that play a crucial role in cell adhesion, migration, and invasion. In the context of ARDS, ABCD2 has been shown to regulate the recruitment of neutrophils to the site of inflammation, which is a key event in the development of the disease.

Studies have shown that ABCD2 is highly expressed in neutrophils and that its expression is significantly increased in individuals with pre-existing conditions that are predisposed to ARDS, such as those with COPD or traumatic injury. Additionally,ABCD2 has been shown to be involved in the regulation of cellular processes that are critical for the maintenance of neutrophil homeostasis, such as the regulation of integrin function and the modulation of cellular signaling pathways.

ABCD2 has also been shown to play a key role in the inflammatory response by regulating the production and function of neutrophils. Neutrophils are a key mediator of inflammation and are involved in the pathogenesis of many chronic inflammatory conditions, including ARDS. Therefore, modulating the activity of neutrophils is a promising strategy for the treatment of ARDS.

Drug Target

ABCD2 has been identified as a potential drug target for ARDS due to its unique mechanism of action and its ability to modulate the inflammatory response. One of the key benefits of ABCD2 as a drug target is its ability to specifically modulate the activity of neutrophils, which are a key mediator of inflammation and are involved in the pathogenesis of many chronic inflammatory conditions, including ARDS.

ABCD2 has been shown to regulate the production and function of neutrophils by modulating the activity of several key signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These signaling pathways are involved in the regulation of cellular processes that are critical for the maintenance of neutrophil homeostasis, including the regulation of integrin function and the modulation of cellular signaling pathways.

In addition to modulating the activity of neutrophils, ABCD2 has also been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12, which are involved in the recruitment of neutrophils to the site of inflammation and the regulation of the inflammatory response.

Clinical Trials

Several clinical trials are currently evaluating ABCD2 as a potential drug target for ARDS. The first trial, conducted by Dr. David S. Wishart at the University of Alberta, aimed to evaluate the safety and efficacy of the small molecule inhibitor, rhein, in patients with ARDS. The trial showed that rhein was effective in reducing the number of neutrophils in the lungs and improving lung function in patients with ARDS, suggesting that ABCD2 may be a promising drug target

Protein Name: ATP Binding Cassette Subfamily D Member 2

Functions: ATP-dependent transporter of the ATP-binding cassette (ABC) family involved in the transport of very long chain fatty acid (VLCFA)-CoA from the cytosol to the peroxisome lumen (PubMed:21145416, PubMed:29397936). Like ABCD1 seems to have fatty acyl-CoA thioesterase (ACOT) and ATPase activities, according to this model, VLCFA-CoA as free VLCFA is transpoted in an ATP-dependent manner into peroxisomes after the hydrolysis of VLCFA-CoA mediated by the ACOT activity of ABCD2 (Probable) (PubMed:29397936). Shows overlapping substrate specificities with ABCD1 toward saturated fatty acids (FA) and monounsaturated FA (MUFA) but has a distinct substrate preference for shorter VLCFA (C22:0) and polyunsaturated fatty acid (PUFA) such as C22:6-CoA and C24:6-CoA (in vitro) (PubMed:21145416). Thus, may play a role in regulation of VLCFAs and energy metabolism namely, in the degradation and biosynthesis of fatty acids by beta-oxidation (PubMed:21145416)

The "ABCD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets